BAYN.DE - Bayer Aktiengesellschaft

XETRA - XETRA Delayed price. Currency in EUR
97.92
-0.52 (-0.53%)
At close: 5:35PM CET
Stock chart is not supported by your current browser
Previous close98.44
Open98.71
Bid0.00 x 28400
Ask0.00 x 2100
Day's range97.58 - 98.79
52-week range94.72 - 123.90
Volume2,015,889
Avg. volume2,510,787
Market cap80.999B
BetaN/A
PE ratio (TTM)11.11
EPS (TTM)8.82
Earnings date24 May 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est120.99
  • Reuters - UK Focus13 hours ago

    EU mergers and takeovers (Feb 23)

    The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- U.S. car parts supplier Key Safety Systems, which is a unit of ...

  • EQS Group3 days ago

    Bayer Aktiengesellschaft: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

    Bayer Aktiengesellschaft / Preliminary announcement on the disclosure offinancial statements21.02.2018 / 08:00Preliminary announcement of the publication of financial reports accordingto Articles 114, 115, 117 of the WpHG [the German Securities Act]transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. ...

  • MarketWatch4 days ago

    Perrigo shares decline 1% on news of Bayer lawsuit over generic rosacea product

    Perrigo Co. PLC shares declined 1.2% in premarket trade Tuesday after the company said Bayer AG is suing it over a generic rosacea product after Perrigo filed for Food and Drug Administration approval ...

  • Bayer gets FDA rebuke for drug production in Germany
    Reuters10 days ago

    Bayer gets FDA rebuke for drug production in Germany

    Bayer (BAYGn.DE) said it had received a warning letter from the U.S. Food and Drug Administration over how it handled production of some drugs at its Leverkusen, Germany headquarters. The German drugmaker, which is taking over U.S. seed maker Monsanto (MON.N), is addressing the FDA's complaints regarding manufacturing practices, which stem from a routine inspection in January, Bayer said. "We expect temporary supply limitations affecting our mature product portfolio," though distribution from the Leverkusen supply centre would continue, Bayer said.

  • Reuters10 days ago

    Bayer petitions Russian antitrust watchdog for more time in Monsanto case

    FRANKFURT/MOSCOW (Reuters) - Bayer (BAYGn.DE) has taken Russia's antitrust regulator to court over the watchdog's investigation into the company's planned takeover of Monsanto (MON.N), a further hiccup in the $64 billion deal amid intense antitrust scrutiny. A Bayer spokesman said the German company was petitioning the court in Russia to be given more time to discuss demands made by the regulator about the deal, which would create the world's largest seeds and pesticides company. Bayer made a decision to bring the case to court in order to safeguard its juridical rights," Bayer said in a written statement.

  • Reuters10 days ago

    Bayer petitions Russian antitrust watchdog for more time in Monsanto case

    FRANKFURT/MOSCOW (Reuters) - Bayer has taken Russia's antitrust regulator to court over the watchdog's investigation into the company's planned takeover of Monsanto, a further hiccup in the $64 billion deal amid intense antitrust scrutiny. A Bayer spokesman said the German company was petitioning the court in Russia to be given more time to discuss demands made by the regulator about the deal, which would create the world's largest seeds and pesticides company. Bayer made a decision to bring the case to court in order to safeguard its juridical rights," Bayer said in a written statement.

  • Reuters10 days ago

    Bayer petitions Russian antitrust watchdog for more time in Monsanto case

    FRANKFURT/MOSCOW (Reuters) - Bayer (BAYGn.DE) has taken Russia's antitrust regulator to court over the watchdog's investigation into the company's planned takeover of Monsanto (MON.N), a further hiccup in the $64 billion deal amid intense antitrust scrutiny. A Bayer spokesman said the German company was petitioning the court in Russia to be given more time to discuss demands made by the regulator about the deal, which would create the world's largest seeds and pesticides company. Bayer made a decision to bring the case to court in order to safeguard its juridical rights," Bayer said in a written statement.

  • Reuters - UK Focus11 days ago

    Russian anti-monopoly watchdog says is being sued by Germany's Bayer - RIA

    German's Bayer has taken Russia's Federal Anti-Monopoly Service to court in relation to Bayer's planned deal with U.S. seed-maker Monsanto , the RIA news agency quoted the Russian watchdog as saying on ...

  • Monsanto Battles Market Rivalry on Innovation & Bayer's Deal
    Zacks11 days ago

    Monsanto Battles Market Rivalry on Innovation & Bayer's Deal

    Monsanto Company's (MON) performance to be driven by stronger innovation and Bayer AG's pending buyout deal. However, stiff business rivalry and rising debt remain causes of concern.

  • Reuters - UK Focus11 days ago

    EU mergers and takeovers (Feb 12)

    The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- Swiss logistics group Kuehne + Nagel to acquire sole control of ...

  • Reuters14 days ago

    EU says Bayer Monsanto must not hurt competition in digital farming - paper

    Bayer (BAYGn.DE) needs to ensure that a merger with rival Monsanto (MON.N) does not stifle competition in digital farming, the European Union's Competition Commissioner Margrethe Verstager told a German newspaper on Saturday. Bayer's $63.5 billion takeover of U.S. Monsanto, announced in 2016, is set to create the world's largest seeds and pesticides company.

  • Reuters15 days ago

    Bayer offers vegetable seeds disposal to clinch Monsanto deal - sources

    BRUSSELS/FRANKFURT (Reuters) - Bayer (BAYGn.DE) plans to sell its global vegetable seeds business and allow BASF (BASFn.DE) exclusive access to its digital farming data in an effort to address EU antitrust concerns over its $63.5 billion (45.20 billion pounds) purchase of Monsanto (MON.N), three people close to the matter said on Thursday. The German drug and crop chemicals maker submitted its offer last week after the European Commission said the deal could reduce competition in pesticides, seeds and plant traits such as herbicide tolerance and insect resistance. Bayer clinched a deal in October last year to sell its seed and herbicide businesses to BASF for 5.9 billion euros ($7.2 billion).

  • Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow
    Zacks15 days ago

    Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow

    Regeneron (REGN) fourth-quarter results were encouraging as the company topped both earnings and sales estimates on the back of Eylea sales.

  • Reuters16 days ago

    Brazilian antitrust agency approves Bayer-Monsanto tie-up

    Brazilian antitrust agency Cade on Wednesday approved Bayer AG's proposed takeover of U.S. seeds company Monsanto Co without requiring further asset sales beyond a global proposal announced last October. Cade's commissioners voted 4-2 in favor of the tie-up under an agreement, negotiated between the companies and global antitrust agencies, that included the sale of several of Bayer's assets to BASF SE. Approval of the transaction in Brazil, a powerhouse producer of grains and other agricultural commodities, clears a crucial hurdle for the deal, which the companies initially aimed to have approved by the end of 2017.

  • Reuters16 days ago

    Brazilian antitrust agency approves Bayer-Monsanto tie-up

    Brazilian antitrust agency Cade on Wednesday approved Bayer AG's (BAYGn.DE) proposed takeover of U.S. seeds company Monsanto Co (MON.N) without requiring further asset sales beyond a global proposal announced last October. Cade's commissioners voted 4-2 in favor of the tie-up under an agreement, negotiated between the companies and global antitrust agencies, that included the sale of several of Bayer's assets to BASF SE (BASFn.DE). Approval of the transaction in Brazil, a powerhouse producer of grains and other agricultural commodities, clears a crucial hurdle for the deal, which the companies initially aimed to have approved by the end of 2017.

  • Reuters18 days ago

    Bayer offers to sell businesses to win EU approval for Monsanto deal

    BRUSSELS/FRANKFURT (Reuters) - Bayer has offered to sell seeds and pesticides businesses to try to address EU competition concerns over its $63.5 billion (£45.3 billion) bid for U.S. rival Monsanto. The proposed remedies "are very significant and we are confident they fully address the European Commission's concerns," the German company said in a statement on Monday. The European Commission extended the deadline for its decision on the deal to April 5 from March 12.

  • Barrons.com23 days ago

    [$$] Bayer Buys More Crispr Stock After Celgene Sells

    Crispr Therapeutics’ largest shareholder just invested another $12 million in the Swiss developer of gene-based medicines. Bayer disclosed that on Jan. 5 a subsidiary bought another 527,500 shares of Crispr (CRSP) for $22.75 each in a public offering. Bayer’s total ownership now stands at 5.71 million shares.

  • Reuters25 days ago

    EU review of Bayer's Monsanto bid postponed further

    FRANKFURT/BRUSSELS (Reuters) - Bayer's (BAYGn.DE) quest to win regulatory approval for its planned takeover of Monsanto (MON.N) ran into further delays on Monday as European Union antitrust investigators extended their investigation by five working days until March 12. The EU did not state a reason for the extension to March 12 to deliver its verdict on the merger, which effectively gives Bayer a new deadline at midnight Feb. 5 to propose concessions such as asset sales. A Bayer spokesman declined to comment, beyond confirming the EU's statement.

  • Reuterslast month

    Insight: Battle of the beans - Monsanto faces a fight for soy market

    WINNIPEG, Manitoba/CHICAGO (Reuters) - Monsanto Co is facing major threats to its historic dominance of seed and herbicide technology for the $40 billion U.S. soybean market. Rivals BASF SE and DowDuPont are preparing to push their own varieties of genetically modified soybeans. At stake is control over seed supply for the next generation of farmers producing the most valuable U.S. agricultural export.

  • Reuterslast month

    Battle of the beans: Monsanto faces a fight for soy market

    WINNIPEG, Manitoba/CHICAGO (Reuters) - Monsanto Co (MON.N) is facing major threats to its historic dominance of seed and herbicide technology for the $40 billion U.S. soybean market. Rivals BASF SE (BASFn.DE) and DowDuPont (DWDP.N) are preparing to push their own varieties of genetically modified soybeans. At stake is control over seed supply for the next generation of farmers producing the most valuable U.S. agricultural export.

  • Reuterslast month

    EU mergers and takeovers (Jan 22)

    BRUSSELS, Jan 22 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- Madison Dearborn Partners Enter to ...

  • Reuterslast month

    Bayer raises higher than expected 1.8 billion euros from Covestro placement

    Bayer (BAYGn.DE), the drug company that is buying seed maker Monsanto (MON.N), has raised 1.8 billion euros (1.59 billion pounds) from selling a 10.4 percent stake in Covestro (1COV.DE), nearing a complete divestment from the plastics company. Germany's Bayer in October hinted it would need less cash from shareholders than initially expected to fund the Monsanto deal, worth $63.5 billion including debt, partly because of windfalls from selling down its Covestro holding. Bayer sold 21 million Covestro shares for 86.25 euros apiece overnight, cutting its stake to 14.2 percent, Bayer said on Thursday.

  • Reuterslast month

    Bayer to sell Covestro shares worth about $1.8 billion

    FRANKFURT/MUNICH (Reuters) - German drugs and pesticides group Bayer (BAYGn.DE) on Wednesday said it was selling more of its stake in chemicals group Covestro (1COV.DE), aiming to raise about 1.5 billion euros (£1.33 billion) in an accelerated bookbuilding process. Bayer has said it wants to fully dispose of its holding in Covestro, which it demerged in 2015, in the medium term. Credit Suisse (CSGN.S) and Goldman Sachs (GS.N) are acting as joint bookrunners for the overnight placement, which is aimed at institutional investors and marks the fifth time in 10 months that Bayer has moved to sell Covestro stock.

  • Reuterslast month

    Bayer, J&J win reversal of $28 million verdict in Xarelto lawsuit

    Judge Michael Erdos, in the Philadelphia County Court of Common Pleas, ruled following a hearing on the drugmakers' motion to reverse the December verdict, which was their first trial loss in litigation over the blood thinner, the companies said. J&J's Janssen Pharmaceuticals Inc unit and Bayer, which jointly developed Xarelto, in separate statements welcomed the decision and said they will continue to defend against the allegations in related litigation.

  • Market Realist2 months ago

    How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17

    In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes